Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bio Eleven is a South Korean biotechnology company specializing in microbiome research and high-potency probiotic products. The company is widely recognized for its De Simone brand, which utilizes a clinically validated formulation of eight probiotic strains to manage gastrointestinal conditions such as irritable bowel syndrome and ulcerative colitis. In 2022, Bio Eleven was acquired by TiumBio, a clinical-stage biopharmaceutical company, to synergize microbiome expertise with drug development capabilities. Bio Eleven operates the Kim Seok-jin Probiotics Research Institute and offers Ttobak, a personalized health service that provides customized probiotic subscriptions based on individual gut microbiome analysis. The company continues to develop next-generation live biotherapeutic products targeting immune and inflammatory diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bio Eleven.